Loading
A phase 2 trial of regorafenib in colorectal cancer, run by Centre Hospitalier Universitaire de Besancon, now recruiting.
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers is a phase 2, randomised interventional study registered as NCT06425133 by Centre Hospitalier Universitaire de Besancon, with a registry enrolment figure of 174 participants, started 2024-07-19 and due to reach its primary completion in 2027-09. Interventions recorded: Blood sample; Quality of life questionnaires; Biopsy; Regorafenib; Regorafenib + metronomic chemotherapy. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: To evaluate the impact of a Regorafenib combined with metronomic chemotherapy and low-dose aspirin compared to standard Regorafenib treatment by assessing progression-free survival. Colorectal eligibility wording from the registry: "Patients with histologically proven metastatic colorectal cancer in progression after previous standard treatments (5FU, CPT11 (Irinotecan), oxaliplatin, anti-VEGF (vascular endothelial growth factor), trifluridine/tipiracil, anti-EGFR (epidermal growth factor receptor) therapy if KRAS (Kirsten rat ". Sites: France. No results are recorded here; the registry entry is the source.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Mismatch-repair deficient (MSI-high) colorectal cancer, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.